J9
Glucocorticoid resistance inhibitor
Product Specifications
Background
J9, in combination with dexamethasone inhibits cell growth in T-cell acute lymphoblastic leukemia (T-ALL) through the upregulation of the glucocorticoid receptor. Patients can develop glucocorticoid resistance rendering the treatment ineffective. J9 and its mechanism of action provides a useful strategy for overcoming the resistance. The EC50 of J9 in combination with dexamethasone is 28 uM. J9 alone was less toxic.
Product Name Alternative
4-cyclopropyl-5-(pyridin-4-yl)pyrimidin-2-amine
UNSPSC
41116105
Source
Synthetic
Purity
99.9%
Weight
0.01
Format
White Solid
Solubility
Soluble in CDCI3
Molecular Formula
C12H12N4
Molecular Weight
212.26
Precautions
Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
References & Citations
1. Cantley A.M., et al. (2014) ACS Medicinal Chemistry Letters 5.7: 754-759.
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1160247-01 1 mg (E-Coli)
Recombinant Bacillus subtilis Alpha-ketoglutarate permease (csbX), partial
Ask
View Details 
MBS1160247-02 1 mg (Yeast)
Recombinant Bacillus subtilis Alpha-ketoglutarate permease (csbX), partial
Ask
View Details 